References
- Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–634.
- Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110:1149–1161.
- Musallam KM, Uthman I, Taher AT. Antiphospholipid syndrome, microalbuminuria, and risk of venous thromboembolism. JAMA 2009;302:945; author reply 945–946.
- Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–423.
- Connolly G. The impact of bortezomib on the risk of thrombosis in multiple myeloma. Leuk Res 2011;35:145–146.
- Tynngard N, Lindahl TL, Ramstrom S. Assays of different aspects of haemostasis - what do they measure? Thromb J 2015;13:8.
- Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma 2015;56:3418–3425.
- Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 2014;133(Suppl. 2): S35–38.
- Burbury KGP, Choo A, Curnow J, et al. Novel thrombogenic biomarkers in patients with relapsed/refractory multiple myeloma treated with lenalidomide and dexamethasone therapy. ASH Abstract 3187; 2010.